{"id":1808,"date":"2017-10-09T23:12:12","date_gmt":"2017-10-09T23:12:12","guid":{"rendered":"http:\/\/entrogen.com\/web4\/?page_id=1808"},"modified":"2022-10-13T20:36:18","modified_gmt":"2022-10-13T20:36:18","slug":"lung-cancer-gene-panel-alk-ret-ros1","status":"publish","type":"page","link":"https:\/\/entrogen.com\/web4\/lung-cancer-gene-panel-alk-ret-ros1\/","title":{"rendered":"Lung Cancer RNA Panel"},"content":{"rendered":"[et_pb_section fullwidth=”on” specialty=”off”][et_pb_fullwidth_header admin_label=”Fullwidth Header” title=”Lung Cancer RNA Panel (ALK, RET, ROS1 & MET Mutations)” background_layout=”dark” text_orientation=”left” module_class=”product-page-header” \/][\/et_pb_section][et_pb_section][et_pb_row][et_pb_column type=”2_3″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”]\n

Available Now<\/h2>\n
\n\n\n\n\n
Product Name\/Description <\/strong><\/th>\n\n
No. of Reactions*<\/strong><\/div>\n<\/th>\n
Product Code <\/strong><\/th>\n<\/tr>\n
Lung Cancer RNA Panel (ROS1, RET, ALK & MET Mutations)<\/td>\n\n
48<\/div>\n<\/td>\n
LUNG-RT48<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

* Includes all controls<\/p>\n

Fusion Genes in Lung Cancer<\/h4>\n

Non\u2013small-cell lung cancer (NSCLC) is frequently associated with aberrant tyrosine kinase activity that abnormally activates downstream signaling pathways. Aberrant tyrosine kinase activity has been linked to chromosomal translocations involving ALK, ROS1 and RET which are found in 3-7%, ~2%, and ~1% of patients with NSCLC, respectively. The presence of ALK and ROS1 fusion genes predicts response to several recently approved tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib and alectinib). Lung cancer patients harboring RET fusion genes may be candidates for RET inhibitors (vandetanib and cabozantinib) which are approved for thyroid cancer treatment.<\/p>\n<\/div>\n

MET exon 14 skipping mutations are also frequently detected in lung adenocarcinoma and occur in 3-4% of patients. Patients that are positive for MET exon 14 skipping mutations show increased sensitivity to MET inhibitors, including crizotinib and cabozantinib.<\/p>\n

<\/h3>\n

Kit Features<\/h4>\n

The Lung Cancer RNA Panel provides reagents for detecting ALK, ROS1, and RET fusion genes as well as MET exon 14 skipping mutations in human lung RNA.<\/p>\n

The one-step assay combines first-strand cDNA synthesis (reverse transcription) and subsequent amplification of mutant and reference genes, minimizing hands-on time and reducing the risk of introducing contaminants during the workflow. The kit detects a total of 47 variants (see tables below) in 8 reactions.<\/p>\n

This kit is compatible with various sample types and can be used to detect mutations in RNA isolated from fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
ALK Fusion Gene Variant<\/strong><\/th>\nChromosomal Translocation<\/strong><\/th>\n<\/tr>\n
EML4-ALK<\/td>\nE13;A20<\/td>\n<\/tr>\n
E20;A20<\/td>\n<\/tr>\n
E20;ins18A20<\/td>\n<\/tr>\n
E6;A20<\/td>\n<\/tr>\n
E6ins33;A20<\/td>\n<\/tr>\n
E6;ins18A20<\/td>\n<\/tr>\n
E14ins11;del49A20<\/td>\n<\/tr>\n
E2;A20<\/td>\n<\/tr>\n
E2;ins117A20<\/td>\n<\/tr>\n
E13;ins69A20<\/td>\n<\/tr>\n
E14;del14A20<\/td>\n<\/tr>\n
E14;del36A20<\/td>\n<\/tr>\n
E17;ins30A20<\/td>\n<\/tr>\n
E17ins61;ins34A20<\/td>\n<\/tr>\n
E17del58ins39;A20<\/td>\n<\/tr>\n
E17ins65;A20<\/td>\n<\/tr>\n
E17;ins68A20<\/td>\n<\/tr>\n
E15del60;del71A20<\/td>\n<\/tr>\n
E18;A20<\/td>\n<\/tr>\n
E3;ins53A20<\/td>\n<\/tr>\n
E6;A19<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
ROS1 Fusion Gene Variant<\/strong><\/th>\nChromosomal Translocation<\/strong><\/th>\n<\/tr>\n
SLC34A2-ROS1<\/td>\nS4;R32<\/td>\n<\/tr>\n
S13del;R32<\/td>\n<\/tr>\n
S4;R34<\/td>\n<\/tr>\n
S13del;R34<\/td>\n<\/tr>\n
CD74-ROS1<\/td>\nC6;R32<\/td>\n<\/tr>\n
C7;R32<\/td>\n<\/tr>\n
C6;R34<\/td>\n<\/tr>\n
SDC4-ROS1<\/td>\nS2;R32<\/td>\n<\/tr>\n
S4;R32<\/td>\n<\/tr>\n
S4;R34<\/td>\n<\/tr>\n
EZR-ROS1<\/td>\nE10;R34<\/td>\n<\/tr>\n
LRIG3-ROS1<\/td>\nL16;R35<\/td>\n<\/tr>\n
TPM3-ROS1<\/td>\nT8;R35<\/td>\n<\/tr>\n
GOPC-ROS1<\/td>\nG7;R35<\/td>\n<\/tr>\n
G4;R36<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
RET Fusion Gene Variant<\/strong><\/th>\nChromosomal Translocation<\/strong><\/th>\n<\/tr>\n
KIF5B-RET<\/td>\nK15;R12<\/td>\n<\/tr>\n
K16;R12<\/td>\n<\/tr>\n
K22;R12<\/td>\n<\/tr>\n
K23;R12<\/td>\n<\/tr>\n
K24;R8<\/td>\n<\/tr>\n
K24;R11<\/td>\n<\/tr>\n
K15;R11<\/td>\n<\/tr>\n
CCDC6-RET<\/td>\nC1;R12<\/td>\n<\/tr>\n
NCOA4-RET<\/td>\nN6;R12<\/td>\n<\/tr>\n
TRIM33-RET<\/td>\nT14;R12<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
Gene<\/strong><\/th>\nMutation<\/strong><\/th>\n<\/tr>\n
MET<\/td>\nExon 14 skipping<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Equipment & Materials<\/h4>\n

The Lung Cancer RNA Panel requires a real-time PCR instrument capable of detecting FAM, VIC and CY5 fluorescent probes. This kit includes primer\/probe mix for detection of all variants mentioned above, one-step enzyme mix for cDNA synthesis and PCR detection, as well as validated controls. Columns and reagents for RNA isolation are not included.<\/p>\n<\/div>\n

 <\/p>\n

Intended Use<\/h4>\n

USA: <\/strong><\/p>\n

EntroGen\u2019s Lung Fusion Gene Panel is available for research use only (RUO)<\/strong>. Not for use in diagnostic procedures.<\/p>\n

Europe:\u00a0<\/strong><\/p>\n

EntroGen\u2019s Lung Fusion Gene Panel is available for research<\/strong> (RUO<\/strong>) and diagnostic<\/strong> (CE-IVD<\/strong>) purposes.<\/p>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”]\n

\n
\n

Overview<\/h2>\n
\n
\n
\n
\n
\n